The commitment of organizations like the Cystic Fibrosis Foundation to global research funding and access initiatives has further propelled market growth. Additionally, major pharmaceutical companies, ...
Since two groundbreaking treatments were approved in late 2023, only a handful of patients have been able to access the ...
The most recent trading session ended with Vertex Pharmaceuticals (VRTX) standing at $416.96, reflecting a -1.72% shift from the previouse trading day's closing. The stock's performance was behind the ...
Vertex Pharmaceuticals Inc. closed 19.80% below its 52-week high of $519.88, which the company reached on November 8th.
HHS challenges Vertex Pharmaceuticals' fertility services program, alleging violations of anti-kickback laws linked to its ...
Roche's core research spans five large areas. Boris Zaïtra, who now leads corporate business development, is confident his ...
Vertex Pharmaceuticals (NASDAQ: VRTX) is a biotechnology company with a strong track record of success in developing ...
Vertex Pharmaceuticals ( VRTX 3.06%) might be one of those special cases. Should you buy Vertex stock hand over fist before ...
Vertex Pharmaceuticals Inc. closed 18.39% short of its 52-week high of $519.88, which the company reached on November 8th.
Analysis of the S&P 500 health care sector's performance, quant ratings of top companies, and expert opinions on future ...
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...
Ongoing launch of CASGEVY® continues to gain momentum--2025 is poised to be a catalyst-rich year with key updates across several ...